ACTU - Wutah dodolan triwulanan Actuate Therapeutics, Inc.

Tandha merek Actuate Therapeutics, Inc (ACTU)

Geopolitical tensions and sanctions are slowing international scientific exchange, complicating therapy certification for Actuate Therapeutics, Inc. (ACTU). Meanwhile, the expansion of elraglusib through Phase II trials aims to capture the oncology market. Anticipation of inhibitor data amid high R&D costs is impacting share prices. The quarterly revenue growth trend visualizes the cash flow, where the 0.00 mark records this metric.

ACTU (Actuate Therapeutics Inc) riwayat Wutah pendapatan triwulanan saka 14.08.2024 nganti 21.11.2026

Rincian analitis lan laporan data perusahaan Actuate Therapeutics, Inc (ACTU)

Analisis umum perusahaan:Actuate Therapeutics, Inc - ACTU
Produk sing diprodhuksi Actuate Therapeutics Inc.

For the young oncology biotech Actuate Therapeutics, Inc. (ACTU), revenue growth rates serve as an indicator of the commercialization of its GSK-3beta inhibitor developments. This metric measures the percentage change in quarterly revenue, allowing for an assessment of the business's scaling speed. By analyzing this quarterly revenue chart, an investor can see the efficiency of capital allocation by the experienced management team. Steady growth here confirms the asset's market potential, whereas a sharp slowdown could signal stagnation.

Karo sapa Actuate Therapeutics, Inc. saingan

BeiGene Oncology - Wutah pendapatan triwulanan|HALO: Wutah pendapatan kuartal marang kuartal|Revolution Medicines Corp (RVMD) - Wutah pendapatan kuartal marang kuartal|Tingkat wutah pendapatan sajrone kuartal Ascentage Pharma Group International (AAPG)|Wutah pendapatan kuartal marang kuartal CG Oncology, Inc.|Tingkat wutah pendapatan sajrone kuartal UroGen Pharma Corp URGN|Wutah pendapatan triwulanan BCAX|Personalis, Inc. - Wutah dodolan kuartal marang kuartal|Erasca - Wutah dodolan triwulanan|Tambahing pendapatan triwulanan DCTH|YMAB: Wutah dodolan triwulanan|Tingkat wutah pendapatan sajrone kuartal Aura Corp|CADL: Wutah pendapatan triwulanan|ARAY - Tingkat wutah dodolan sajrone kuartal|SLS (SELLAS Life Sciences Group, Inc.) - Wutah pendapatan triwulanan|Wutah dodolan triwulanan Citius Oncology Inc. (CTOR)|Wutah pendapatan kuartal marang kuartal TuHURA (HURA)|TARA - Tingkat wutah pendapatan sajrone kuartal|Wutah pendapatan triwulanan FATE (Fate Therapeutics Inc)|Aadi Bioscience Inc (WHWK) - Tingkat wutah pendapatan sajrone kuartal|TScan - Wutah pendapatan triwulanan|Champions Oncology, Inc. (CSBR) - Wutah dodolan triwulanan|XBIT (XBiotech Inc.) - Wutah dodolan triwulanan|CEL-SCI Corporation (CVM) - Wutah pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal OS Therapies|RADX: Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal artivabio.com (ARTV)|Tingkat wutah dodolan sajrone kuartal Adlai Nortye|Wutah pendapatan triwulanan VERU (Veru Corporation)|Owah-owahan dodolan kuartal marang kuartal TPST (Tempest Tx)|XLO: Wutah dodolan triwulanan|renovarobio.com (RENB) - Wutah dodolan triwulanan|Mural Bio (MURA) - Wutah pendapatan kuartal marang kuartal|Kairos Pharma Inc (KAPA) - Wutah pendapatan triwulanan|Wutah dodolan triwulanan OKUR|CytoMed Therapeutics (GDTC) - Tingkat wutah dodolan sajrone kuartal|Wutah dodolan triwulanan CRIS (Curis Inc.)|Wutah pendapatan triwulanan Apollomics Inc. (APLM)|Wutah pendapatan kuartal marang kuartal Tharimmune Corp THAR|Advanced Biomed Corp - Wutah pendapatan kuartal marang kuartal|GNPX: Wutah dodolan triwulanan|Calidi Biotherapeutics, Inc. (CLDI) - Wutah dodolan triwulanan|SBFM: Wutah pendapatan triwulanan|Wutah dodolan triwulanan Xenetic Biosciences Inc.|Wutah pendapatan kuartal marang kuartal Salarius Pharmaceuticals Inc|PPBT: Tambahing pendapatan triwulanan|Wutah pendapatan triwulanan AONC|BGNE (BeOne Medicines) - Tambahing pendapatan triwulanan|Checkpoint Therapeutics, Inc - Wutah dodolan triwulanan|elevationoncology.com (ELEV) - Tingkat wutah pendapatan sajrone kuartal|iCAD Inc. - Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Ikena Oncology|NTBL: Wutah pendapatan triwulanan|Tingkat wutah pendapatan sajrone kuartal Viracta (VIRX)|MOR (MorphoSys AG) - Wutah pendapatan triwulanan|NAYA: Tambahing pendapatan triwulanan|Wutah pendapatan kuartal marang kuartal Ascentage Pharma Group Ltd (AAPGV)